Olivier J Wouters

Biographic Data

ID2164597
NAMEOlivier J Wouters
GIVEN NAMESOlivier J
FAMILY NAMEWouters
SIGNATUREWOUTERS O J
AFFILIATIONSLondon School of Economics and Political Science
ORCID0000-0002-2514-476X
VERIFIEDYes
TOTAL WORKS15
TOTAL CITATIONS1
WORKS AS AUTHOR9
WORKS AS EDITOR6
FIRST PUBLICATION YEAR2019
LATEST PUBLICATION YEAR2026
H-INDEX1

  • Health insurance in Nigeria

    Open AccessKevin Croke, Chike Nwangwu et al.EDITORARTICLEPLOS Global Public Health2026

    The recent Lancet Commission on Nigeria’s health system highlighted high out of pocket expenditures on health and underfunding of the public health sector as major obstacles to Nigeria’s achievement of the Sustainable Development Goals. Nigeria has sought to address these gaps by extending health insurance coverage. This paper measures health insurance coverage and access to care in Nigeria in 2023, using the first round of the People’s Voice Sur…

  • Access to pediatric medicines in Albania

    Open AccessEriona Petro, Hendrika A van den Ham et al.EDITORARTICLEPLOS Global Public Health2026

    Access to pediatric medications remains a challenge in Albania, with significant implications for child health outcomes. Family doctors often encounter difficulties in prescribing and ensuring access to appropriate treatments. This study aimed to explore prescriber perspectives on the accessibility of pediatric medicines in Albania and to identify key barriers and facilitators affecting access. Between March and April 2024, semi-structured interv…

  • Barriers to accessing high-quality cancer medicines in Cameroon. A qualitative study of the views and practices of regulators and frontline healthcare providers

    Open AccessYauba Saidu, Makia Christine Masong et al.EDITORARTICLEPLOS Global Public Health2026

    Cancer has become a major public health problem in Cameroon. In 2020, 20,000 new cases and 14,000 deaths were registered. Despite its high burden, access to quality medications for this condition continues to be a persistent challenge in the country. This study assessed the perceptions and practices of key stakeholders on barriers to accessing quality anticancer medicines in Cameroon. The overall goal was to generate data on key challenges relate…

  • The Health of Nations Fund

    Open AccessJoonhyuk Cho, Manish Singh et al.EDITORARTICLEPLOS Global Public Health2026

    We explore the design and performance of a “Health of Nations Fund,” a proposed securitization of a biomedical “megafund” that pools capital to invest in a diversified set of global drug development projects. Incorporating assets from four stages of the drug development process as well as royalties from approved therapeutics across eight therapeutic areas, our Monte Carlo simulations show that such a megafund can deliver an annual expected return…

  • Advancing global health access through market shaping

    Open AccessClaire Wagner, Claire M Wagner et al.EDITORARTICLEPLOS Global Public Health2026

    New health products have contributed to major improvements in public health, but many clinically effective interventions still face delays in reaching low- and middle-income countries (LMICs). Market shaping approaches have emerged as a set of tools designed to address such access gaps by influencing prices, supply, and demand. Drawing on practitioner experience and illustrative cases, this paper examines how market shaping mechanisms have been u…

  • Tertiary Patents on Drugs Approved by the FDA

    Open AccessTheodore W Teng, S Sean Tu et al.ARTICLEJAMA Health Forum2026

    The findings of this cohort study suggest that policymakers and regulators should take steps to ensure that tertiary patents are not improperly listed in the Orange Book and that generic competition occurs in a timely fashion

  • Global availability of medications and health technologies for kidney care

    Open AccessDearbhla M Kelly, Erika S W Jones et al.EDITORARTICLEPLOS Global Public Health2025

    A core feature of universal health coverage is equitable access to affordable care not exposing people to financial hardship. This study aims to provide a global overview on availability and access to medications and health technologies for delivery of optimal kidney care. An international survey of stakeholders (clinicians, policymakers, and patient advocates) from countries affiliated to the International Society of Nephrology was conducted fro…

  • Revenue Differences Between Top-Selling Small-Molecule Drugs and Biologics in Medicare

    Open AccessMatthew Vogel, William B Feldman et al.ARTICLEJAMA Health Forum2025

    This study compares the revenues earned by manufacturers 9 vs 13 years following US Food and Drug Administration approval for negotiation-eligible products from 2012 to 2022

  • Prices and Affordability of Essential Medicines in 72 Low-, Middle-, and High-Income Markets

    Open AccessOlivier J Wouters, Cyprien Denolle et al.ARTICLEJAMA Health Forum2025

    The results of this cross-sectional analysis showed significant variation in the prices and affordability of 549 essential medicines across 72 markets in 2022. Strategies to promote equitable drug prices and improve drug affordability are urgently needed

  • The launch of the EU Health Emergency Preparedness and Response Authority (Hera)

    Open AccessOlivier J Wouters, Rebecca Forman et al.ARTICLEHealth Policy2023

    The crowded global health landscape has been joined by the European Union Health Emergency Preparedness and Response Authority (HERA). HERA will assume four broad areas of responsibility: horizon scanning for major health threats; research and development; support for capacity to manufacture drugs, vaccines, and equipment; and procuring and stockpiling key medical countermeasures. In this Health Reform Monitor article, we outline the reform proce…

  • Investments in Research and Development for Supplemental Drug Indications—Implications for Drug Price Negotiations

    Open AccessKerstin Noëlle Vokinger, Gellért Perényi et al.ARTICLEJAMA Health Forum2023

    This Viewpoint compares the research and development costs for a drug’s first indication with supplemental indications to demonstrate that the cost of approval for supplemental indications may be substantially lower

  • Challenges in ensuring global access to Covid-19 vaccines

    Open AccessOlivier J Wouters, Kenneth C Shadlen et al.ARTICLEThe Lancet2021

  • Brexit and the European Medicines Agency—What Next for the Agency and UK Drug Regulators

    Open AccessOlivier J Wouters, Tamara Hervey et al.ARTICLEJAMA Health Forum2020

  • Association between provincial income levels and drug prices in China over the period 2010-2017

    Open AccessWunan Shi, Olivier J Wouters et al.ARTICLESocial Science & Medicine2020References: 31

  • The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period

    Open AccessOlivier J Wouters, Dale M Sandberg et al.ARTICLESocial Science & Medicine2019Cited by: 1References: 41

    We investigated the South African tendering system for medicines to (a) evaluate its impact on prices and market concentration over a 14-year period and (b) analyze the accuracy of government forecasts of drug demand. We calculated Herfindahl-Hirschman indexes to measure market concentration levels based on all pharmaceutical tender contracts issued by the South African government between 2003 and 2016 (n = 8701). We estimated price indexes to tr…